A Phase 3, Multicentre, Randomised, Investigator-Blinded, Parallel-group Study of the Safety and Efficacy of Intravenous Daptomycin (Cubicin) Compared With That of Comparator (Vancomycin or Vancomycin Followed by Semi-Synthetic Penicillin-Cloxacillin) in the Treatment of Chinese Subjects With cSSSI.

Trial Profile

A Phase 3, Multicentre, Randomised, Investigator-Blinded, Parallel-group Study of the Safety and Efficacy of Intravenous Daptomycin (Cubicin) Compared With That of Comparator (Vancomycin or Vancomycin Followed by Semi-Synthetic Penicillin-Cloxacillin) in the Treatment of Chinese Subjects With cSSSI.

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Mar 2015

At a glance

  • Drugs Daptomycin (Primary) ; Cloxacillin; Vancomycin
  • Indications Gram-positive infections; Skin and soft tissue infections
  • Focus Adverse reactions; Registrational
  • Sponsors AstraZeneca
  • Most Recent Events

    • 10 Sep 2010 Actual end date added to 1 Sep 2010 as reported by ClinicalTrials.gov.
    • 10 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top